Toll-interacting protein modulates colitis susceptibility in mice

Michel H Maillard1, Hristina Bega, Holm H Uhlig

  • 1*Service of Gastroenterology and Hepatology, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland; †Translational Gastroenterology Unit, Division of Experimental Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom; ‡M2iSH, UMR1071 Inserm, Université d'Auvergne, USC-INRA 2018, Clermont-Ferrand, France; §Institut Universitaire de Technologie en Génie Biologique, Aubière, France; ‖Univ Lille Nord de France, Lille, France; ¶Institut Pasteur de Lille, Center for Infection and Immunity of Lille, Lille, France; **Centre National de la Recherche Scientifique, Unité Mixte de Recherche 8204, Lille, France; ††Institut National de la Santé et de la Recherche Médicale, U1019, Team 7, Equipe FRM, Lille, France; and ‡‡La Source-Beaulieu, Lausanne, Switzerland.

Inflammatory Bowel Diseases
|February 28, 2014
PubMed
Summary

Toll-interacting protein (Tollip) is crucial for maintaining intestinal homeostasis and preventing colitis. Tollip deficiency in nonhematopoietic cells exacerbates inflammatory bowel disease, highlighting its protective role in the gut epithelium.